Targets › CCDC6
4 programs from 3 companies in 14 trials: 7 Phase 2, 3 Phase 3, 2 Phase 4, 2 Phase 1; Oncology; next expected readout Nov 2026.
Acts as a structural scaffold that organizes free PP2Ac into a configuration that FBXO42 can recognize and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination. (UniProt, Q16204)
Open in Phaseline: the race on CCDC6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals | Pralsetinib Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor | RET, CCDC6, KIF5B | Phase 4 | NSCLC (Non-small Cell Lung Cancer) | Jul 2027 |
| Eli Lilly | Selpercatinib Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | RET, KIF5B, CCDC6 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Solid Tumor; Medullary Thyroid Cancer … | Feb 2027 |
| Eli Lilly | Selpercatinib (LY3527723) Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | RET, KIF5B, CCDC6 | Phase 3 | Medullary Thyroid Cancer | Nov 2027 |
| Roche | Pralsetinib Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor | RET, CCDC6, KIF5B | Phase 2 | Non-small Cell Lung Cancer; Advanced Thyroid Cancer Patients Who Received Target Therapy; Lung Cancer Stage III | Nov 2026 |
Non-Small Cell Lung Cancer (2) Medullary Thyroid Cancer (2) Non-small Cell Lung Cancer (1) Advanced Thyroid Cancer Patients Who Received Target Therapy (1) Lung Cancer Stage III (1) Carcinoma, Non-Small-Cell Lung (1) Solid Tumor (1) Recurrent Lung Non-Small Cell Carcinoma (1) Hematopoietic and Lymphatic System Neoplasm (1) Malignant Thyroid Gland Neoplasm (1) Differentiated Thyroid Cancer (1) NSCLC (Non-small Cell Lung Cancer) (1)
small molecule (3), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.